Last reviewed · How we verify

LJPC-501 — Competitive Intelligence Brief

LJPC-501 (LJPC-501) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Complement C5a receptor antagonist. Area: Immunology / Inflammation.

phase 3 Complement C5a receptor antagonist C5a receptor (C5aR) Immunology / Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

LJPC-501 (LJPC-501) — La Jolla Pharmaceutical Company. LJPC-501 is a recombinant human C5a receptor antagonist that blocks complement activation and reduces inflammatory cell recruitment.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LJPC-501 TARGET LJPC-501 La Jolla Pharmaceutical Company phase 3 Complement C5a receptor antagonist C5a receptor (C5aR)
KK8398 KK8398 Kyowa Kirin Co., Ltd. phase 3 Complement C5a receptor antagonist C5aR1 (C5a receptor 1)
MP-513 MP-513 Tanabe Pharma Corporation phase 3 Complement C5a receptor antagonist C5a receptor (C5aR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Complement C5a receptor antagonist class)

  1. Astellas Pharma Global Development, Inc. · 1 drug in this class
  2. Kyowa Kirin Co., Ltd. · 1 drug in this class
  3. La Jolla Pharmaceutical Company · 1 drug in this class
  4. Tanabe Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LJPC-501 — Competitive Intelligence Brief. https://druglandscape.com/ci/ljpc-501. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: